Who
Kaufman Beth Zelnick
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, CorMedix.
In numbers
- Trades disclosed
- 24
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $670K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 12 Dec 2023
- Last trade
- 29 Aug 2026
- Last filed
- 1 Sep 2026
Companies traded
Activity over time
1 Sep 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Aug 2026filed 1 Sep 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code F | $70K8,424 at $8.30 | filing |
| 29 Aug 2026filed 1 Sep 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code F | $70K8,424 at $8.30 | filing |
| 4 Feb 2026filed 6 Feb 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | —36,006 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | —36,006 at $0.00 | filing |
| 23 Jan 2026filed 27 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | —72,820 at $0.00 | filing |
| 23 Jan 2026filed 27 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code F | $64K8,803 at $7.27 | filing |
| 23 Jan 2026filed 27 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | —72,820 at $0.00 | filing |
| 23 Jan 2026filed 27 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code F | $64K8,803 at $7.27 | filing |
| 2 Jan 2026filed 6 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code F | $138K11,333 at $12.16 | filing |
| 2 Jan 2026filed 6 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code F | $138K11,333 at $12.16 | filing |
| 9 Sep 2025filed 11 Sep 2025 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 9 Sep 2025filed 11 Sep 2025 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code M | $165K50,000 at $3.30 | filing |
| 9 Sep 2025filed 11 Sep 2025 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Sold | $665K49,600 at $13.41 | filing |
| 9 Sep 2025filed 11 Sep 2025 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Sold | $5,128400 at $12.82 | filing |
| 29 Aug 2025filed 8 Sep 2025 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code F | $132K8,880 at $14.83 | filing |
| 29 Aug 2025filed 3 Sep 2025 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | —69,686 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | —87,500 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code F | $97K11,844 at $8.22 | filing |
| 12 Dec 2024filed 18 Dec 2024 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code F | $53K6,044 at $8.77 | filing |
| 12 Dec 2024filed 16 Dec 2024 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —12,500 at $0.00 | filing |
News
Head-To-Head Survey: Inhibikase Therapeutics (NASDAQ:IKT) versus CorMedix (NASDAQ:CRMD)CRMD · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name Kaufman Beth Zelnick; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.